GENFLEET-B (02595) announced that it will present preclinical research data for three product candidates during the poster session at the 2026 AACR Annual Meeting. The products are GFH276 (a non-degradative molecular glue), GFS784 (a novel conjugate drug linking a functional antibody with a mechanistically synergistic targeted payload), and GFH603 (a molecular glue-like covalent allosteric activator). The company's RAS therapy portfolio focuses on various selective and pan-RAS inhibitors and continues to investigate potential targets of important co-mutations within the RAS pathway. This portfolio includes diverse molecular formats and multi-mechanism RAS pathway-related large and small molecule targeted drugs. The AACR Annual Meeting will be held from April 17 to April 22, 2026, in San Diego, USA. The company's posters will be presented on April 19 and April 21 respectively.